세계 망막 생물학적 제제 시장 : 약제 클래스별, 적응증별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Retinal Biologics Market size was valued at USD 22,345 Million in 2023, expanding at a CAGR of 7.5% from 2024 to 2032.

Specialized therapeutic compounds called retinal biologics are used to treat a variety of retinal conditions, including diabetic retinopathy and macular degeneration. These biologics, which include proteins and antibodies produced from living things, are made to specifically target molecules or processes associated with retinal disorders. They provide more effective treatment alternatives than traditional techniques by offering tailored medicines that address the underlying processes of retinal diseases. Usually, intravitreal injections are used to give retinal biologics, which entail injecting the drug right into the eye.

Retinal Biologics Market- Market Dynamics

Increasing prevalence of diabetes and macular degeneration to propel market demand

The increasing prevalence of diabetes and macular degeneration across the globe is expected to drive the retinal biologics market over the forecast period. For instance, according to the data published by the Diabetes Research Institute Foundation, 11.3% of Americans, or 37.3 million individuals, suffer from diabetes. 28.7 million persons were projected to have been diagnosed with diabetes. 8.6 million people worldwide suffer from diabetes but are not yet aware of their condition. Similarly, as per the data provided by the CDC, 19.8 million Americans (or 12.6% of the population) over 40 had age-related macular degeneration (AMD) in 2019. Thus, the aforementioned statistics are expected to propel the revenue growth of the market.

Retinal Biologics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2024-2032)

Based on drug class segmentation, the VEGF-A Antagonist sector dominates the market

Based on indication segmentation, the macular degeneration held the largest market share in 2023

Based on distribution channel segmentation, the hospital pharmacies dominate the market

Based on region, North America was the leading revenue generator in 2023

Retinal Biologics Market- Segmentation Analysis:

The Global Retinal Biologics Market is segmented based on Drug Class, Indication, Distribution Channel, and Region.

The market is divided into two categories based on drug class: TNF-a Inhibitor and VEGF-A Antagonist. The VEGF-A Antagonist sector dominates the market. The segment expansion is attributed to the growing product approvals. For instance, Novartis disclosed that Beovu® (brolucizumab) injection is now authorized by the European Commission (EC) to treat wet age-related macular degeneration (AMD). Beovu is the first anti-VEGF medication licensed by the European Commission that has shown better resolution of retinal fluid (IRF/SRF), a crucial indicator of disease activity, in comparison to aflibercept (secondary endpoints).

The market is divided into four categories based on indication: diabetic retinopathy, macular degeneration, uveitis and others. Macular degeneration held the largest market share in 2023 and is expected to continue the same pattern during the forecast period due to the growing number of drugs being developed for macular degeneration and the condition's increasing global incidence. For instance, in September 2022 research released by the National Library of Medicine predicted that over 300 million people worldwide will have age-related macular degeneration (AMD) by the year 2040.

The market is divided into three categories based on distribution channel: hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies dominate the market and are likely to maintain their dominance during the forecast period due to the availability of various types of medication.

Retinal Biologics Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to lead the retinal biologics market during the forecast period. The regional expansion is attributed to the presence of major market players and the approvals of their products. For instance, in August 2023, Veopoz (pozelimab-bbfg), a monoclonal antibody, was authorized by the FDA by Regeneron Pharmaceuticals to treat CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, in adults and pediatric patients one year of age and older. Additionally, the firm reported that the FDA has authorized Eylea HD (aflibercept) Injection 8 mg, a high-dose form of Eylea, for the treatment of diabetic retinopathy, diabetic macular edema, and wet age-related macular degeneration (wAMD). Furthermore, the increasing prevalence of diabetes and the prevalence of macular degeneration is expected to propel the market growth in the region.

Retinal Biologics Market- Competitive Landscape:

The key players operating in the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co Inc, Bayer AG, AbbVie Inc., Janssen Biotech, Boehringer Ingelheim International GmbH, AstraZeneca plc, Fresenius SE, Teva Pharmaceuticals Industries Ltd., Novartis AG, Amgen Inc, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd. and Bristol-Myers Squibb. To obtain access to new markets, market players are continuously pursuing a variety of strategic initiatives, including the creation of new products, funding and investments, mergers and acquisitions, and other strategic partnerships.

Recent Developments:

In June 2023, Wacker Biotech, a contract development and manufacturing organization (CDMO), and Caeregen Therapeutics, a regenerative medicine therapeutics company, will work together to develop and produce CTR-107 (NoregenTM), a novel regenerative therapeutic for the treatment of retinal-related vision loss. To facilitate the start of Phase I/II clinical studies in 2024, Wacker Biotech, as Caeregen's CDMO partner for CTR-107, will create drug substance at its location in Halle, Germany, and complete clinical trial drug product manufacturing at its location in Amsterdam, the Netherlands. The first program to treat familial exudative vitreoretinopathy (FEVR) to get a Rare Pediatric Disease Designation from the US FDA is CTR-107.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RETINAL BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

F. Hoffmann-La Roche Ltd

Pfizer Inc.

Merck & Co. Inc

Bayer AG

AbbVie Inc.

Janssen Biotech

Boehringer Ingelheim International GmbH

AstraZeneca plc

Fresenius SE

Teva Pharmaceuticals Industries Ltd.

Novartis AG

Amgen Inc

Regeneron Pharmaceuticals Inc

Sun Pharmaceutical Industries Ltd.

Bristol-Myers Squibb

GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

• TNF-a Inhibitor
• VEGF-A Antagonist

GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

• Diabetic Retinopathy
• Macular Degeneration
• Uveitis
• Others

GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

GLOBAL RETINAL BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Retinal Biologics Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Retinal Biologics Market Snippet by Drug Class
  • 2.1.2. Retinal Biologics Market Snippet by Indication
  • 2.1.3. Retinal Biologics Market Snippet by Distribution Channel
  • 2.1.4. Retinal Biologics Market Snippet by Country
  • 2.1.5. Retinal Biologics Market Snippet by Region
• 2.2. Competitive Insights

3. Retinal Biologics Key Market Trends

• 3.1. Retinal Biologics Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Retinal Biologics Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Retinal Biologics Market Opportunities
• 3.4. Retinal Biologics Market Future Trends

4. Retinal Biologics Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Retinal Biologics Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Retinal Biologics Market Landscape

• 6.1. Retinal Biologics Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Retinal Biologics Market - By Drug Class

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
  • 7.1.2. TNF-a Inhibitor
  • 7.1.3. VEGF-A Antagonist

8. Retinal Biologics Market - By Indication

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
  • 8.1.2. Diabetic Retinopathy
  • 8.1.3. Macular Degeneration
  • 8.1.4. Uveitis
  • 8.1.5. Others

9. Retinal Biologics Market - By Distribution Channel

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
  • 9.1.2. Hospital Pharmacies
  • 9.1.3. Retail Pharmacies
  • 9.1.4. Online Pharmacies

10. Retinal Biologics Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Retinal Biologics Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Retinal Biologics Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Retinal Biologics Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Retinal Biologics Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Retinal Biologics Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Retinal Biologics Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. F. Hoffmann-La Roche Ltd
  • 11.2.2. Pfizer Inc.
  • 11.2.3. Merck & Co Inc
  • 11.2.4. Bayer AG
  • 11.2.5. AbbVie Inc.
  • 11.2.6. Janssen Biotech
  • 11.2.7. Boehringer Ingelheim International GmbH
  • 11.2.8. AstraZeneca plc
  • 11.2.9. Fresenius SE
  • 11.2.10. Teva Pharmaceuticals Industries Ltd.
  • 11.2.11. Novartis AG
  • 11.2.12. Amgen Inc
  • 11.2.13. Regeneron Pharmaceuticals Inc
  • 11.2.14. Sun Pharmaceutical Industries Ltd.
  • 11.2.15. Bristol-Myers Squibb

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us